Truist ‘optimistic’ on Compugen’s approach after Roche data leak

Truist remains “optimistic” that Compugen (CGEN) is able to demonstrate a differentiated clinical profile with its dual blockade of the DNAM-1 axis with both TIGIT and PVRIG inhibition versus TIGIT alone after “broadly leaked” data from Roche’s (RHHBY) SKYSCRAPER-01 trial evaluating tiragolumab plus atezolizumab vs atezolizumab alone in first-line PD-L1-high advanced non-small cell lung cancer. Truist keeps a Buy rating and $4 price target on Compugen shares.